GRAIL, Inc. (GRAL) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Robust short-term growth supported by 26-28% revenue growth, rising test volumes, upcoming FDA PMA submission, strategic international investments, and strong technical momentum with a 24.7% price rise over 21 days, while significant losses and cash burn risk temper longer-term upside.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Liquidity Cushion ⢠Cash Burn ⢠Weak Profitability GRAL's strong liquidity and low leverage are offset by persistent losses, heavy cash burn, and an intangible-heavy balance sheet that leaves the investment case financially resilient but operationally weak.
Price Behavior
Key Price Behavior Insights: ⢠Late-May surge ⢠Support holding ⢠Failed breakout Support Level: $59.65-$60.00 Resistance Level: $66.55-$67.86, then $71.68-$73.92 Over the last month, GRAL surged into late May but then reversed sharply below both its peak and starting level, leaving $60 support intact for now but with a failed-breakout risk if $59.65 breaks.
Sentiment & News
Key News Insights: ⢠Mixed trial results ⢠FDA catalyst ⢠Coverage outlook GRAIL's ASCO readouts triggered a volatile reaction as investors weighed mixed NHS-Galleri results against stronger PATHFINDER 2 data and future FDA/coverage catalysts.
AI Summary
GRAL has moved from a pure optionality story to a test of whether Galleri's commercial traction can overcome unresolved clinical and reimbursement questions, and investors should focus on payer-backed demand scaling fast enough to outrun ongoing cash burn and dilution risk; until that happens, it looks more like a catalyst-driven, high-volatility trade than a self-funding growth business.
Description
GRAIL, Inc. is a biotechnology firm based in Menlo Park, California, established in 2015. The company develops blood-based tests intended to detect cancer at early stages in asymptomatic individuals and to support faster diagnostic resolution when cancer is suspected, as well as tests for minimal residual disease and other post-diagnostic uses. GRAIL previously operated as a subsidiary of Illumina, Inc.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 26 | Dec 3 | GRAL | GRAIL, Inc. | Robust short-term growth supported by 26-28% revenue growth, rising test volumes, upcoming FDA PMA submission, strategic international investments, and strong technical momentum with a 24.7% price rise over 21 days, while significant losses and cash burn risk temper longer-term upside. | Closed | -8.1% |